A new report on Crestor is raising safety concerns AGAIN

A new report on Crestor is raising safety concerns AGAIN.

This analysis suggests a trend towards more cases of severe myopathy and a higher rate of proteinuria with Crestor.

The FDA looked at this data previously...and decided to leave Crestor on the market for now. They say the incidence of side effects with Crestor is similar to that of the other statins.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote